Skip to main content

LeonaBio, Inc.

LONA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001620463

No open-market purchases or sales by LeonaBio, Inc. insiders were filed in the last 90 days; 44 institutions reported holding it in 13F filings for Q2 2026, worth $66.8M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by LeonaBio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for LeonaBio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for LeonaBio, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Edelman JosephDirector, 10% Owner329,756IndirectJul 10, 20265
Perceptive Advisors LLCDirector, 10% Owner329,756IndirectJul 10, 20263
Perceptive Life Sciences Master Fund LtdDirector, 10% Owner329,756IndirectJul 10, 20263
Johnson James ADirector5,000Jun 24, 20262
Pickering GrantDirector25,783Jun 24, 20262
Holles Natalie C.Director–Jun 24, 20262
Panzara Michael A.Director–Jun 24, 20262
Romano Kelly ADirector80,715Jun 24, 20262
Kosacz BarbaraDirector–Jun 24, 20262
Silverman Peter B.Director–Jun 24, 20262
Callori FredDirector–Jun 24, 20262
Fluke John M JrDirector–Apr 13, 20261
Litton Mark JamesPRESIDENT and CEO57,926Apr 13, 20264
San Martin JavierCHIEF MEDICAL OFFICER15,887Apr 13, 20264
Church KevinCHIEF SCIENTIFIC OFFICER25,178Apr 13, 20264
Worthington MarkGENERAL COUNSEL and CCO18,376Apr 13, 20264
Renninger RobertCHIEF FINANCIAL OFFICER15,851Apr 13, 20264
Perceptive Xontogeny Venture Fund II, LPDirector, 10% Owner329,756IndirectDec 23, 20251
Gengos AndrewCFO and Chief Business Officer97,532Sep 5, 20240
Lenington RachelCOO and CDO20,870Sep 5, 20240
Moebius HansChief Medical Officer91,482Jan 8, 20240
Mileson GlennaChief Financial Officer159,930Jan 23, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 5, 2026 (view filing)Mar 41 dayRenninger RobertCHIEF FINANCIAL OFFICERSSale−906$5.37−$4.87K−5.4%15.9K after
Mar 5, 2026 (view filing)Mar 41 dayWorthington MarkGENERAL COUNSEL and CCOSSale−1.33K$5.37−$7.13K−6.7%18.4K after
Mar 5, 2026 (view filing)Mar 41 dayChurch KevinCHIEF SCIENTIFIC OFFICERSSale−1.36K$5.37−$7.30K−5.1%25.2K after
Mar 5, 2026 (view filing)Mar 41 daySan Martin JavierCHIEF MEDICAL OFFICERSSale−1.72K$5.37−$9.24K−9.8%15.9K after
Mar 5, 2026 (view filing)Mar 41 dayLitton Mark JamesPRESIDENT and CEOSSale−5.16K$5.37−$27.7K−8.2%57.9K after
Jan 5, 2026 (view filing)Jan 23 daysRenninger RobertChief Financial OfficerSSale−297$6.88−$2.04K−2.3%12.9K after
Jan 5, 2026 (view filing)Jan 23 daysWorthington MarkGeneral Counsel and CCOSSale−876$6.88−$6.03K−5.9%14.0K after
Jan 5, 2026 (view filing)Jan 23 daysChurch KevinCHIEF SCIENTIFIC OFFICERSSale−876$6.88−$6.03K−4.1%20.7K after
Jan 5, 2026 (view filing)Jan 23 daysSan Martin JavierCHIEF MEDICAL OFFICERSSale−1.64K$6.88−$11.3K−13.9%10.2K after
Jan 5, 2026 (view filing)Jan 23 daysLitton Mark JamesPresident and CEOSSale−2.59K$6.88−$17.8K−6.0%40.8K after
Jul 2, 2025 (view filing)4:35 PM ETJul 11 dayChurch KevinCHIEF SCIENTIFIC OFFICERSSale−8.53K$0.2935−$2.50K−4.8%168.9K after
Jul 2, 2025 (view filing)4:34 PM ETJul 11 dayLitton Mark JamesPresident and CEOSSale−25.1K$0.2935−$7.37K−7.2%325.8K after
Jul 2, 2025 (view filing)4:33 PM ETJul 11 daySan Martin JavierCHIEF MEDICAL OFFICERSSale−10.8K$0.2935−$3.18K−13.1%71.7K after
Jul 2, 2025 (view filing)4:33 PM ETJul 11 dayWorthington MarkGeneral Counsel and CCOSSale−8.53K$0.2935−$2.50K−7.1%111.9K after
Jul 2, 2025 (view filing)4:32 PM ETJul 11 dayRenninger RobertSVP, Finance and AccountingSSale−2.90K$0.2935−$850.27−2.6%109.2K after
Jan 3, 2025 (view filing)Jan 21 daySan Martin JavierCHIEF MEDICAL OFFICERSSale−10.8K$0.56−$6.06K−23.2%35.8K after
Jan 3, 2025 (view filing)Jan 21 dayLitton Mark JamesPresident and CEOSSale−25.1K$0.56−$14.1K−9.4%242.6K after
Jan 3, 2025 (view filing)Jan 21 dayChurch KevinCHIEF SCIENTIFIC OFFICERSSale−8.51K$0.56−$4.77K−6.1%130.8K after
Jan 3, 2025 (view filing)Jan 21 dayRenninger RobertVP of FinanceSSale−2.88K$0.56−$1.61K−3.1%89.7K after
Jan 3, 2025 (view filing)Jan 21 dayWorthington MarkGeneral Counsel and CCOSSale−8.51K$0.56−$4.77K−9.2%83.7K after
Sep 5, 2024 (view filing)Sep 5Same dayGengos AndrewCFO and Chief Business OfficerSSale−1.27K$0.57−$725.04−1.3%97.5K after
Sep 5, 2024 (view filing)Sep 5Same dayLenington RachelCOO and CDOSSale−2.52K$0.57−$1.44K−10.8%20.9K after
Sep 5, 2024 (view filing)Sep 5Same dayChurch KevinCHIEF SCIENTIFIC OFFICERSSale−2.52K$0.57−$1.44K−2.7%92.7K after
Sep 5, 2024 (view filing)Sep 5Same dayWorthington MarkGENERAL COUNSELSSale−2.52K$0.57−$1.44K−4.6%51.9K after
Sep 5, 2024 (view filing)Sep 5Same dayLitton Mark JamesPresident and CEOSSale−5.03K$0.57−$2.87K−3.1%159.4K after
Jun 25, 2024 (view filing)Jun 21-244 daysRomano Kelly ADirectorPPurchase+42.4K$2.36+$100.2K+110.7%80.7K after2 lots
Feb 16, 2024 (view filing)Jan 542 daysLenington RachelCOO AND CDOSSale−2.41K$2.91−$7.02K−15.3%13.4K afterAmended
Feb 16, 2024 (view filing)Jan 542 daysLitton Mark JamesCEOSSale−4.82K$2.91−$14.0K−3.2%144.4K afterAmended
Feb 16, 2024 (view filing)Jan 542 daysWorthington MarkGENERAL COUNSELSSale−2.41K$2.91−$7.02K−6.5%34.5K afterAmended
Feb 16, 2024 (view filing)Jan 542 daysGengos AndrewCFO AND CHIEF BUSINESS OFFICERSSale−1.21K$2.91−$3.52K−1.4%83.8K afterAmended
Feb 16, 2024 (view filing)Jan 542 daysChurch KevinCHIEF SCIENTIFIC OFFICERSSale−2.41K$2.91−$7.02K−2.9%80.3K afterAmended
Dec 29, 2023 (view filing)5:24 PM ETDec 27-292 daysEdelman Joseph and 2 othersDirector, 10% OwnerPPurchase+605.7K$2.42+$1.46M+12.6%5.40M after3 lots
Jun 9, 2023 (view filing)Jun 72 daysGengos AndrewSee BelowPPurchase+15.0K$3.43+$51.5K+23.1%80.0K after3 lots
Jun 6, 2023 (view filing)Jun 2-54 daysGengos AndrewSee BelowPPurchase+65.0K$2.95+$191.6KNew position65.0K after7 lots
Mar 31, 2023 (view filing)Mar 29-302 daysPickering GrantDirectorPPurchase+25.0K$2.41+$60.4K+3,192.8%25.8K after2 lots
Mar 30, 2023 (view filing)Mar 291 dayJohnson James ADirectorPPurchase+5.00K$2.40+$12.0KNew position5.00K after
Dec 30, 2022 (view filing)Dec 282 daysMileson GlennaChief Financial OfficerPPurchase+50.0K$2.85+$142.5K+45.5%159.9K after
Dec 6, 2022 (view filing)Dec 24 daysRomano Kelly ADirectorPPurchase+30.0K$3.29+$98.7K+360.8%38.3K after
Nov 17, 2022 (view filing)Nov 152 daysMoebius HansChief Medical OfficerPPurchase+5.00K$3.29+$16.4K+8.2%65.8K after
Jul 1, 2022 (view filing)2:24 PM ETJun 29-302 daysEdelman Joseph and 2 othersDirector, 10% OwnerPPurchase+1.37M$2.99+$4.10M+40.0%4.80M after2 lots
Jun 30, 2022 (view filing)Jun 282 daysMoebius HansChief Medical OfficerPPurchase+10.0K$2.88+$28.8K+23.3%53.0K after
Jun 24, 2022 (view filing)Jun 231 dayWorthington MarkGeneral CounselSSale−2.61K$2.69−$7.03K−12.0%19.1K after
Jun 24, 2022 (view filing)Jun 231 dayMileson GlennaChief Financial OfficerSSale−2.61K$2.69−$7.03K−2.3%109.2K after
Jun 24, 2022 (view filing)Jun 231 dayLitton Mark JamesChief Executive OfficerSSale−7.96K$2.69−$21.4K−5.8%128.6K after
Jun 24, 2022 (view filing)Jun 231 dayLenington RachelChief Operating OfficerSSale−4.19K$2.69−$11.3K−41.9%5.81K after
Jun 24, 2022 (view filing)Jun 231 dayChurch KevinExecutive VP, ResearchSSale−2.61K$2.69−$7.03K−4.3%57.7K after
Apr 1, 2022 (view filing)Mar 311 dayRomano Kelly ADirectorPPurchase+8.00K$13.11+$104.9K+2,539.7%8.31K after